Realizable cash to a minority ≈ ₩13,841/sh vs ₩18,120 market · −24% · NAV ceiling ₩30,766 is a vault you don’t hold the key to
SELL — market price exceeds the cash a minority can realize; the NAV backing is trappedCosmax BTI is the listed holding company of Korea’s Cosmax group, and it is a dual-lens valuation. The realizable number — the cash a minority actually receives (a ~2% dividend, growing ~3.5%, that is not even covered by FCF, plus a small catalyst option) — is worth ≈₩13,841/share, 24% below the ₩18,120 market price (a cash-to-minority dividend look-through). The NAV ceiling — what the assets are worth to the controller — is ₩30,766 (the DCF NAV number, after modelling capital laziness in the flows, marking the trapped 27% Cosmax Inc stake control-net to ₩435B, and a residual 15% governance haircut). The ₩16,925/sh gap between the two lenses is the trap: Korean controlled holdcos trade below NAV for decades, and a minority can be right on NAV and collect nothing. On the realizable lens this is a Sell pending a named catalyst (buyback-and-cancellation, holdco/opco merger, or activist/NPS ≥5% filing), not a clean buy. This rebuilds v1, which mis-stated a +96% “buy” by carrying the stake gross and bolting a flat 45% discount on the end.
What it sells, where it sells
Operating segments
This donut is only the directly-consolidated operating businesses — the ₩338B enterprise value the FCFF DCF actually prices. The crown jewel (the 27.24% Cosmax Inc associate) is equity-method, so its ₩31B of income sits in non-operating investment income and its ₩435B market value is carried separately as a cross-holding, not in this revenue line.
Country mix (revenue-weighted CRP input)
This is the geography of the CONSOLIDATED OPCO only — Korea-dominant, with the ~25% foreign weight being NBT supplement export demand (US / China / Indonesia). It deliberately does not reflect the China/US-heavy Cosmax Inc associate, which is a separate cross-holding marked to market; mixing the two would double-count the group's foreign exposure.
Background — five things to know before the case
Context the share price doesn't carry on its face. Skim this once and the bull / bear bullets below stop reading as inside baseball.
- This is the listed holding company, not the famous ODM. Cosmax BTI (KRX:044820) is the control vehicle of Korea's Cosmax group. The business most people mean by "Cosmax" is the separately-listed ₩2.4T-revenue ODM, Cosmax Inc (KRX:192820) — which BTI owns only 27.24% of, equity-method.
- The market prices the whole holdco below just its listed stake. BTI's ~₩173B market cap (₩18,120 × 9.55M sh) is roughly one-quarter of the ₩435B market value of its Cosmax Inc stake alone — before counting the consolidated opcos or netting debt. That is the entire thesis: an enormous, persistent NAV discount.
- The consolidated opcos are marginal and heavily levered. FY2025 consolidated revenue ₩645.2B, operating income only ₩27.0B (4.2% margin); standalone earnings have drifted down ~9%/yr over five years. Total debt ₩513.9B vs ₩107.2B cash; net interest cover ~1.0x. The dividend cash-payout ratio runs ~173% — paid from the associate pickup, not opco FCF.
- The crown jewel is firing. Cosmax Inc posted a record FY2025 (₩2.4T revenue, ₩196B OP), with China re-accelerating (+20% Q1'26) and the US subsidiary at a breakeven inflection. We carry the stake at market (~₩220k/sh) — conservative versus ₩230–290k sell-side targets — rather than re-DCF'ing it.
- Eight-year succession just resolved — through private shell companies. The May 2026 change of largest shareholder (to eldest son Lee Byung-man) was executed via private shells (S&S/SSY, BGH, CosM&M, Recipe) — classic chaebol related-party machinery. The family holds ~53.5%; the holdco exists partly as a control vehicle, not a value-maximizer for minorities.
Where we diverge from the sector
Each row asks: if we'd used the sector median for this one assumption instead of our override, how much would the share price change? Negative = our override is more conservative (worth less); positive = more aggressive (worth more). Skim down the rightmost column to see which bets are doing the work.
The story & the five claims
The 10-year story this DCF is built on, plus the five anchor claims that translate the story into model inputs.
The 10-year story
Cosmax BTI is not really an operating company you value with a single DCF — it is the listed holding company of Korea's Cosmax group, and its worth is a sum of two very different parts. The first part is the small, heavily-indebted set of businesses it actually consolidates: health-functional-food maker Cosmax NBT, cosmetic packaging, raw materials and logistics. Together those did ₩645B of revenue last year at a thin 4.2% operating margin, with earnings that have shrunk about 9% a year for five years; the FCFF model values that whole pool at only ₩338B of enterprise value. The second part — and the reason anyone looks at this stock — is a 27.24% stake in the separately-listed Cosmax Inc, the ₩2.4 trillion-revenue ODM that is currently firing on all cylinders. That stake is worth about ₩680B gross at today's market price; net of ~20% look-through capital-gains tax and a 20% control-realization haircut — BTI holds only a 27% minority of it, and cannot force it to pay or sell — we carry it at ₩435B. Add the stake to the opco, subtract the group's ₩407B of net debt, and statutory net-asset value comes to roughly ₩36,195 a share. Then we apply only a 15% residual haircut — because the governance load already lives in the flows (terminal ROC set to its cost of capital, so reinvested capital earns zero excess return) and in the control-net stake mark, leaving the end-discount to price residual leakage and dilution alone — to land at ₩30,766. Against a ₩18,120 price that NAV ceiling still looks like a +70% gap, but it is a ceiling, not a target: the cash a minority actually receives is worth ≈₩13,841/sh — 24% below the price — the discount has every reason to stay open, and without a buyback or a NAV-closing event a minority holder can wait a very long time to collect it.
Two debates worth pressure-testing
- We treat the number as a NAV ceiling, not a price target. Sell-side that looks at this name anchors on the statutory NAV gap; we model governance in the flows, mark the stake control-net, apply only a 15% residual haircut — and still flag that the realizable cash-to-minority (≈₩13,841) sits below market, so the NAV gap may never close without a catalyst.
- Crown jewel carried at market, not re-DCF'd. We resist the temptation to value Cosmax Inc higher — marking the stake to a conservative ~₩220k keeps the thesis honest and the debate on the haircut.
- β set to 1.78 by sector anti-suppression, not the ~0.68 regression. A 0.68 equity β at D/E ~3x implies β_u ≈ 0.21, below any food company — clearly an illiquidity artifact, so we re-lever the sector unlevered β instead.
- Governance modelled in the flows, not a flat end-discount. Capital laziness enters as terminal ROC ≈ WACC (zero excess return) and the 27% stake is marked control-net; the residual end-discount is just 15%, well inside the 0–30% band. This corrects v1, which crammed the whole thesis into a flat 45% knob.
- Opco WACC is flattered and we say so. Consolidated book debt loads the debt weight to ~0.75, pulling WACC to ~6%; much of that debt actually carries the Cosmax Inc stake, so the opco EV is an upper-ish estimate. It barely matters — the stake and net debt dwarf the opco DCF.
- The discount never closes — the value-trap case. This is the central bear case, and the one the 0% probability-below-market cannot capture. Korean controlled holdcos trade 50–70% below NAV for decades. No buyback, no NAV-closing event, management indifferent: a minority holder can be right on value and still collect nothing for years.
- The controlling family routes cash for its own ends. The holdco is a succession vehicle; the May 2026 control change ran through private shells, and there is a history of dilutive discounted issuance to minorities. The 15% haircut prices this; a worse-than-modelled related-party drain would justify even more.
- The crown jewel re-rates down. ₩435B of the value is one marked-to-market stake. Cosmax Inc trades on a China re-acceleration and a US breakeven inflection; a China stumble or a strong-KRW translation hit would cut the stake — and the Monte Carlo already varies it across the ₩155k–₩287k 52-week range.
- Opco leverage bites in a downturn. ₩513.9B debt, ~1.0x interest cover, a dividend paid above opco FCF. If the associate pickup falters, the consolidated balance sheet is fragile and the ~Caa/CCC synthetic rating is not cosmetic.
- No catalyst, no coverage, no float. ~0% institutional ownership, ~3.5M-share float, 12 nominal analysts and zero submitting estimates. Even if the gap should close, there is no marginal informed buyer positioned to close it.
Risks to thesis (tail, not bear case)
The defining risk and the one the 0% prob-below-market does not price. Korean controlled holdcos trade 50–70% below NAV for decades. With no buyback, no NAV-closing event and an indifferent family, a minority holder can be right on value and collect nothing for years. This is a sell on realizable cash pending a named catalyst, not a clean buy.
~53.5% family-held; the holdco is a succession vehicle run through private shell companies (S&S/SSY, BGH, CosM&M), with a history of dilutive discounted issuance to minorities. The 15% haircut prices the structural tax; a worse outcome justifies more.
₩435B — the bulk of value — is one marked-to-market stake in Cosmax Inc. A China stumble (it is currently +20% Q1'26) or strong-KRW translation hit cuts the stake; the Monte Carlo varies it across the ₩155k–₩287k 52-week band.
₩513.9B debt vs ₩107.2B cash, net interest cover ~1.0x, dividend cash-payout ~173% (funded by the associate pickup, not opco FCF). Synthetic credit ~Caa/CCC. Fragile if the equity-method income falters.
~3.5M-share float and stale pricing suppress the regression β and distort the MC inputs. We address it by re-levering the sector β_u (1.78), but thin liquidity is a real friction for a minority position.
Cosmax NBT sits in a structurally soft Korean health-functional-food market; the export tailwind (US / SE-Asia) only partly offsets it. A drag on the opco — but the opco is a rounding error next to the stake.
10-year forecast
Opco revenue ₩664.6B → ₩867.1B over 10y (~3% fading to 2.5% terminal); operating margin lifts from 4.2% to 5.0%, staying below the 8.5% Food Processing global median. This chart is the ₩338B opco only — the ₩435B Cosmax Inc cross-holding and the 15% residual governance haircut, which drive the result, are outside it.
Monte Carlo distribution
Across 1,000 correlated stress draws the p5 outcome is ₩27.4k/share, still +51% above the ₩18,120 price, and not one draw lands below the market — hence P(intrinsic < market) = 0.0%. But that 0% prices only the sampled input distributions (opco operating spread + the stake's 52-week range). It does not capture the real risk: that the structural NAV discount simply never closes. Read the band as a NAV ceiling, not a probability of profit.
Mean ₩30910.33 ± ₩5615.63/sh, 1000 iterations (0 failed). P(intrinsic < market ₩18120.00) = 1.0%.
Cost of capital build
| Risk-free rate | 2.80% |
| Mature-market ERP | 4.23% |
| Levered β | 1.78 |
| Weighted CRP | 0.70% |
| Cost of equity | 11.60% |
| Pre-tax cost of debt (synth Caa/CCC) | 5.50% |
| D / V | ~75% |
| WACC | 5.95% |
Full year-by-year DCF
| Year | Revenue | Op mgn | EBIT | EBIT(1−t) | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | ₩664.56B | 4.27% | ₩28.35B | ₩21.26B | ₩11.39B | ₩9.88B | ₩9.32B |
| 2 | ₩684.49B | 4.35% | ₩29.76B | ₩22.32B | ₩11.73B | ₩10.59B | ₩9.44B |
| 3 | ₩705.03B | 4.43% | ₩31.23B | ₩23.42B | ₩12.08B | ₩11.34B | ₩9.54B |
| 4 | ₩726.18B | 4.51% | ₩32.76B | ₩24.57B | ₩12.44B | ₩12.13B | ₩9.62B |
| 5 | ₩747.96B | 4.59% | ₩34.35B | ₩25.76B | ₩12.81B | ₩12.95B | ₩9.70B |
| 6 | ₩770.40B | 4.67% | ₩36.01B | ₩26.91B | ₩13.20B | ₩13.71B | ₩9.69B |
| 7 | ₩793.51B | 4.76% | ₩37.73B | ₩28.09B | ₩13.60B | ₩14.49B | ₩9.67B |
| 8 | ₩817.32B | 4.84% | ₩39.53B | ₩29.32B | ₩14.00B | ₩15.31B | ₩9.64B |
| 9 | ₩841.84B | 4.92% | ₩41.41B | ₩30.59B | ₩14.42B | ₩16.17B | ₩9.61B |
| 10 | ₩867.09B | 5.00% | ₩43.35B | ₩31.91B | ₩14.86B | ₩17.05B | ₩9.57B |
Methodology & flags
Damodaran FCFF DCF, 10y explicit + perpetuity, in KRW. Risk-free
2.80% (local-currency government bond). Synthetic credit Caa/CCC.
CRP 0.70% from revenue-weighted country mix × Damodaran 2026 CRPs.
Terminal ROIC faded to 6.00%; 15% governance haircut applied
post-DCF. Monte Carlo: 1000 iterations. Engine v1.0.0 · result:
/Users/valentin/Documents/notes_jiliac_labs/Finance/Damodaran/valuations/cosmaxbti-v2/output/2026-06-01-result.json
- R&D cap: OFF · Lease cap: OFF · Failure: OFF · ESO: OFF
- Governance haircut: 15% applied post-DCF (₩36195.31 > ₩30766.01)
- Sensitivity tornado: not run